Advanced search
Publication Cover
Clinical Toxicology Volume 49, 2011 - Issue 9
Submit an article Journal homepage
668
Views
25
CrossRef citations to date
0
Altmetric
Rapid Communication

Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms

Marco VinettiCliniques St-Luc, Université catholique de Louvain, Intensive Care, Avenue Hippocrate 10, Brussels, 1200 BelgiumCorrespondence[email protected]
,
Vincent HaufroidUniversité catholique de Louvain, Louvain Centre for Toxicology and Applied Pharmacology, Avenue Hippocrate 10, Brussels, 1200 Belgium
,
Arnaud CapronUniversité catholique de Louvain, Louvain Centre for Toxicology and Applied Pharmacology, Avenue Hippocrate 10, Brussels, 1200 Belgium
,
Jean-François ClassenUniversité catholique de Louvain, Louvain Centre for Toxicology and Applied Pharmacology, Avenue Hippocrate 10, Brussels, 1200 Belgium
,
Sebastien MarchandiseCliniques St-Luc, Cardiology, Avenue Hippocrate 10, Brussels, 1200 Belgium
&
Philippe HantsonCliniques St-Luc, Université catholique de Louvain, Intensive Care, Avenue Hippocrate 10, Brussels, 1200 Belgium
Pages 865-869 | Received 27 Apr 2011, Accepted 16 Sep 2011, Published online: 14 Nov 2011

References

  • Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 2007; 64:192–197.
  • Isbister G. Electrocardiogram changes and arrhythmias in venlafaxine overdose. Br J Clin Pharmacol 2009; 67:572–576.
  • Mazur JE, Doty JD, Krygiel AS. Fatality related to a 30-g venlafaxine overdose. Pharmacotherapy 2003; 23:1668–1772.
  • Höjer J, Hulting J, Salmonson H. Fatal cardiotoxicity induced by venlafaxine overdosage. Clin Toxicol 2008; 46:336–337.
  • Fangio P, De Jonghe B, Appéré-De-Vecchi C, Lachérade JC, Tervile JP, Outin H, Dagorn J. Acute heart failure associated with venlafaxine poisoning. Am J Emerg Med 2007; 25:210–211.
  • Khalifa M, Daleau P, Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999; 291:280–284.
  • Partridge SJ, MacIver DH, Solanki T. A depressed myocardium. J Toxicol Clin Toxicol 2000; 38:453–455.
  • Christoph M, Ebner B, Stolte D, Ibrahim K, Kolschmann S, Strasser RH, Schön S. Broken heart syndrome: Tako tsubo cardiomyopathy associated with an overdose of the serotonin-norpepinephrine reuptake inhibitor venlafaxine. Eur Neuropsychopharmacol 2010; 20:594–597.
  • Caroselli C, Ricci G. The venlafaxine “heart revenge”: a short report. Clin Cardiol 2010; 33:e46–e-47.
  • Godkar D, Stensby J, Sinnapunayagam S, Niranjan S. Venlafaxine induced acute myocardial infarction with normal coronary arteries. Am J Ther 2009; 16:365–366.
  • Wilson AD, Howell C, Waring WS. Venlafaxine ingestion is associated with rhabdomyolysis in adults: a case series. J Toxicol Sci 2007; 32:97–101.
  • Mégarbane B, Bloch V, Deye N, Baud FJ. Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose. Intensive Care Med 2007; 33:195–196.
  • McAlpine DE, Biernacka JM, Mrazek DA, O'Kane DJ, Stevens SR, Langman LJ, . Effect of Cytochrome P450 enzyme polymorphisms on pharmacokinetics of Venlafaxine. Ther Drug Monit 2011; 33:14–20.
  • Kandasamy M, Srinivas P, Subramaniam K, Ravi S, John J, Shekar R, . Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes – focus on venlafaxine and O-desmethylvenlafaxine. Eur J Clin Pharmacol 2010; 66:879–887.
  • Blythe D, Hackett LP. Cardiovascular and neurological toxicity of venlafaxine. Hum Exp Toxicol 1999; 18:309–313.
  • Lessard E, Yessine MA, Hamelin BA, O’Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9:435–43.
  • Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79:103–113.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.